✦ LIBER ✦

Erratum to: pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients

✍ Scribed by Gabriele Buda; Enrico Orciuolo; Sara Galimberti; Matteo Pelosini; Mario Petrini

Publisher: Springer
Year: 2011
Tongue: English
Weight: 47 KB
Volume: 90
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1203-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pegylated liposomal doxorubicin in combi

Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients

✍ Gabriele Buda; Enrico Orciuolo; Sara Galimberti; Matteo Pelosini; Mario Petrini 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 66 KB

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

Polymorphisms in the multiple drug resis

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

✍ Gabriele Buda; Deborah Ricci; C. Chris Huang; Reyna Favis; Nadine Cohen; Sen H. 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 264 KB